• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign

    11/1/23 7:00:00 AM ET
    $ABCM
    $DHR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $ABCM alert in real time by email

    Statement from Dr. Jonathan Milner on the suspension of the "Vote AGAINST" campaign

    CAMBRIDGE, England, 1 November 2023 - Jonathan Milner, the founder and one of the largest investors in Abcam plc ("Abcam" or the "Company") (NYSE:ABCM) with ownership of 6.16% of the Company, today issued the following statement in relation to the proposed acquisition of Abcam by Danaher Corporation (NYSE:DHR) or its affiliates ("Danaher").

    "After extensive feedback from the majority of Abcam's shareholders, I have today decided to suspend my "Vote AGAINST" campaign. It has become clear that a significant majority intend to support Danaher's acquisition of Abcam and I respect this decision and will not stand in the way of the deal.

    Although this outcome is not what I envisioned, I accept the result and wish Abcam and Danaher all the best for their future. My sincere gratitude goes to everyone who supported my campaign over the last few months, especially to my shadow Board nominees: your bravery and loyalty have been deeply appreciated. A special thanks also goes to my team of advisors who, acting with integrity and honesty, ensured every shareholder's voice was heard.

    Since the start of my campaign, Abcam's share price increased significantly and, despite the final outcome, I sincerely believe that our campaign has shown that it is possible to stand up to, and call out, an ineffective Board and Management who displayed disregard for the interests of shareholders. It also drew attention to key metrics, governance issues, and the performance of Executive Directors. It is disappointing that, confronted with these facts, Abcam's Board and leadership team decided to simply put the Company up for sale and accept a subpar offer, at the expense of loyal and long-term shareholders. I hope that my actions will inspire shareholders in other companies to hold their Boards to account.

    I extend my heartfelt best wishes to the dedicated staff and loyal customers of Abcam. May they find continued success under the new ownership of Danaher."

    Ends

    Jonathan Milner

    https://abcamfocus.com/

    Investor contact

    Alliance Advisors (Europe)

    T: +44 7733 265 198 / E: [email protected]

    Michael Roper

    Alliance Advisors (US)

    T: +1 917 414 4766

    Thomas Ball

    Peel Hunt LLP

    T: +44 (0) 20 7418 8900

    Christopher Golden / James Steel

    Sohail Akbar / Jock Maxwell Macdonald

    International PR advisers

    ICR Consilium (Europe)

    T: +44 (0)20 3709 5700 / E: [email protected]

    Mary-Jane Elliott / Matthew Neal / Davide Salvi

    ICR (US)

    T: +1 646 677 1811 / E: [email protected]

    Dan McDermott



    Get the next $ABCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ABCM
    $DHR

    CompanyDatePrice TargetRatingAnalyst
    Danaher Corporation
    $DHR
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    Danaher Corporation
    $DHR
    3/21/2025$260.00Neutral → Buy
    Goldman
    Danaher Corporation
    $DHR
    3/14/2025$260.00Hold → Buy
    Stifel
    Danaher Corporation
    $DHR
    2/3/2025Outperform → Mkt Perform
    Raymond James
    Danaher Corporation
    $DHR
    12/23/2024Sector Perform
    Scotiabank
    Danaher Corporation
    $DHR
    12/19/2024$275.00Buy
    Guggenheim
    Danaher Corporation
    $DHR
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    Danaher Corporation
    $DHR
    10/31/2024$285.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $ABCM
    $DHR
    SEC Filings

    See more
    • SEC Form 11-K filed by Danaher Corporation

      11-K - DANAHER CORP /DE/ (0000313616) (Filer)

      6/17/25 8:19:40 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • SEC Form SD filed by Danaher Corporation

      SD - DANAHER CORP /DE/ (0000313616) (Filer)

      5/12/25 4:39:59 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - DANAHER CORP /DE/ (0000313616) (Filer)

      5/8/25 4:36:17 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $ABCM
    $DHR
    Financials

    Live finance-specific insights

    See more
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Quarterly Dividend

      WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h

      5/6/25 4:15:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Reports First Quarter 2025 Results

      WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to $5.7 billion and non-GAAP core revenue was flat year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Revenue, earnings, and cash flow exceeded our expectations in the first quarter–highlighted by continued momentum in bioprocessing and better-

      4/22/25 6:00:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $ABCM
    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director List Teri exercised 3,928 shares at a strike of $59.34 and covered exercise/tax liability with 1,150 shares, increasing direct ownership by 13% to 23,517 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/7/25 5:00:12 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • New insider Milosevich Gregory M claimed ownership of 4,455 shares (SEC Form 3)

      3 - DANAHER CORP /DE/ (0000313616) (Issuer)

      7/1/25 5:00:51 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Director Stevens Raymond C was granted 577 shares, increasing direct ownership by 5% to 12,361 units (SEC Form 4)

      4 - DANAHER CORP /DE/ (0000313616) (Issuer)

      5/19/25 5:02:20 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $ABCM
    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Schedules Second Quarter 2025 Earnings Conference Call

      WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

      6/17/25 4:30:00 PM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $ABCM
    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Danaher upgraded by Barclays with a new price target

      Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00

      4/10/25 8:28:29 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Goldman with a new price target

      Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00

      3/21/25 8:01:35 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher upgraded by Stifel with a new price target

      Stifel upgraded Danaher from Hold to Buy and set a new price target of $260.00

      3/14/25 7:34:47 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials

    $ABCM
    $DHR
    Leadership Updates

    Live Leadership Updates

    See more
    • Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

      6/27/25 7:35:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

      WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. "Greg has played a pivotal role in advancing our Life Sciences Innovations Group over the past f

      6/27/25 7:30:00 AM ET
      $DHR
      Industrial Machinery/Components
      Industrials
    • Danaher Announces Appointment of Charles Lamanna to Danaher Board

      WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee. Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ:MSFT), where he drives product innovation in AI-powered business applications, low-code platforms, and autonomous agents. He oversees the design, product development, and engineering of some of Microsoft's most transformative technologies, including Power Platform, Dynamics 365, and Copilot Studio. Prior to that, Mr. Lamanna was the founder and CEO of MetricsHub, one of the first public cloud

      2/20/25 4:45:00 PM ET
      $DHR
      $MSFT
      Industrial Machinery/Components
      Industrials
      Computer Software: Prepackaged Software
      Technology

    $ABCM
    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      2/12/24 5:24:03 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Abcam plc (Amendment)

      SC 13G/A - Abcam plc (0001492074) (Subject)

      1/12/24 11:40:16 AM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Abcam plc (Amendment)

      SC 13D/A - Abcam plc (0001492074) (Subject)

      12/8/23 4:30:10 PM ET
      $ABCM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care